Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM)

• Main Authors: Brice Amadeo, Nicolas Penel, Jean-Michel Coindre, Isabelle Ray-Coquard, Karine Ligier, Patricia Delafosse, Anne-Marie Bouvier, Sandrine Plouvier, Justine Gallet, Aude Lacourt, Gaëlle Coureau, Alain Monnereau, Simone Mathoulin-Pélissier, Emmanuel Desandes
• Format: Article
• Language: English
• Published: BMC 2020-03-01
• Series: BMC Cancer
• Subjects: Sarcoma; Incidence; Trends in incidence; France; Cancer registry
• Online Access: http://link.springer.com/article/10.1186/s12885-020-6683-0

Abstract Background The exhaustive collection of new sarcoma cases and their second histologic review offer a unique opportunity to study their incidence and time trends in France according to the major subtypes. Methods Data were collected from population-based cancer registries covering 22% of the French population. Crude and world age-standardized incidence rates (ASR) were estimated according to anatomic, histological and genetic groups, age and sex over the 2010–2013 period. Results Time trends in incidence were calculated by the annual percent change over the 2000–2013 period. During the most recent period (2010–2013), 3942 patients with sarcoma were included. The ASR of soft-tissue and bone sarcomas, and gastro-intestinal stromal tumors (GIST) were 2.1, 1.0 and 0.6, respectively. For the four most frequent histological subtypes (unclassified, leiomyosarcoma, GIST and liposarcoma), the ASR ranged from 0.4 to 0.7. ASRs were 1.9 for complex genomic and 1.3 for recurrent translocation sarcomas. The time-trend analysis showed a significant increase of sarcoma incidence rate between 2000 and 2005, which stabilized thereafter. Incidence rates increased for four histological subtypes (GIST, chondrosarcoma, myxofibrosarcoma, solitary fibrous tumors) and decreased for three (leiomyosarcomas, Kaposi sarcoma and fibrosarcoma). Conclusion To our knowledge, this study is the first to investigate sarcoma incidence based on a systematic pathological review of these cancers and on the updated sarcoma classifications. Due to the paucity of literature on sarcomas, future studies using data from population-based cancer registries should consider a standardized inclusion criterion presented in our study to better describe and compare data between countries.